← Issue №17/ week of Oct 25, 2026/Colorectal

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal rct · n=400 · Oct 24, 2026 · Lancet · IF 98.4

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

New evidencecolorectal cancer
Clinical takeawayConsider the 14-day trifluridine-tipiracil plus bevacizumab schedule for refractory metastatic colorectal cancer to reduce toxicity, including neutropenia, while maintaining survival outcomes compared to the 28-day schedule.
What it foundThe 14-day trifluridine-tipiracil plus bevacizumab schedule showed non-inferior overall survival (HR 0.93, 95% CI 0.80-1.08) compared to the 28-day schedule, with median survival of 11.3 vs 10.3 months.
ContextThis confirms the 14-day schedule as a viable alternative to the conventional 28-day regimen, addressing toxicity concerns without compromising survival.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sakakida T … PRABITAS investigators · The Lancet · IF 98.4 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues